This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MT 100

Aralez Pharmaceuticals Inc.

Drug Names(s): naproxen sodium and metoclopramide hydrochloride

Description: Metoclopramide is an antiemetic and gastroprokinetic agent. It binds to dopamine D2 receptors where it is a receptor antagonist, and is also a mixed 5-HT3 receptor antagonist/5-HT4 receptor agonist.

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties. The major mechanism of action of NSAIDS is believed to be inhibition of cycloxygenase activity and prostaglandin synthesis.

Deal Structure: In June 2003, Pozen signed a license agreement with Nycomed for the commercialization of MT 100 in four Nordic countries. Under the terms of the agreement, Nycomed will have exclusive rights in Denmark, Sweden, Norway and Finland to commercialize MT 100. Upon execution of the agreement, Nycomed paid an upfront fee of $0.5 million. Pozen is eligible to receive milestone payments in an aggregate amount of between $0.5 million and $1.0 million as well as royalties.

In January 2001, Pozen entered into a Commercial Supply Agreement with DSM Pharmaceuticals, Inc. (formerly Catalytica Pharmaceuticals, Inc.) under which DSM will supply all MT 100 for domestic and non-domestic commercial sale.

In May 2011, Takeda Pharmaceutical and Nycomed A/S jointly announced that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the company for 9.6 billion Euro on a cash-free, debt-free basis. The purchase would exclude Nycomed's U.S. dermatology business....See full deal structure in Biomedtracker

Partners: Takeda Pharmaceutical Company Ltd


MT 100 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug